Evidence map›Paper›PMID 29690504›Full record

ArticleCancers2018

Selective Inhibition of Histone Deacetylation in Melanoma Increases Targeted Gene Delivery by a Bacteriophage Viral Vector.

Samuel Campbell, Keittisak Suwan, Sajee Waramit, Eric Ofori Aboagye, Amin Hajitou

Open access · goldAbstract read
In one paragraph

Article in Cancers, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.4field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Best of most possible worlds: Hybrid gene therapy vectors based on parvoviruses and heterologous viruses.Molecular therapy : the journal of the American Society of Gene Therapy · 2021
    Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Samuel CampbellCancer Phage Therapy Laboratory, Division of Brain Sciences, Burlington Danes Building, Hammersmith Hospital Campus, Imperial College London, Du Cane Road, London W12 0NN, UK. samuel.campbell@zoo.ox.ac.uk.
Keittisak SuwanCancer Phage Therapy Laboratory, Division of Brain Sciences, Burlington Danes Building, Hammersmith Hospital Campus, Imperial College London, Du Cane Road, London W12 0NN, UK. Keittisak.suwan@imperial.ac.uk.
Sajee WaramitCancer Phage Therapy Laboratory, Division of Brain Sciences, Burlington Danes Building, Hammersmith Hospital Campus, Imperial College London, Du Cane Road, London W12 0NN, UK. s.waramit15@imperial.ac.uk.
Eric Ofori AboagyeComprehensive Cancer Imaging Centre, Faculty of Medicine, Hammersmith Hospital Campus, Imperial College London, Du Cane Road, London W12 0NN, UK. eric.aboagye@imperial.ac.uk.
Amin HajitouCancer Phage Therapy Laboratory, Division of Brain Sciences, Burlington Danes Building, Hammersmith Hospital Campus, Imperial College London, Du Cane Road, London W12 0NN, UK. a.hajitou@imperial.ac.uk.
Imperial College London · GBHammersmith Hospital · GB

Funding

Cancer Research UK 25887Medical Research Council G0701159
6 · The paper itself

Abstract

The previously developed adeno-associated virus/phage (AAVP) vector, a hybrid between M13 bacteriophage (phage) viruses that infect bacteria only and human Adeno-Associated Virus (AAV), is a promising tool in targeted gene therapy against cancer. AAVP can be administered systemically and made tissue specific through the use of ligand-directed targeting. Cancer cells and tumor-associated blood vessels overexpress the α

Indexed as

bacteriophageC1AHDAC6HDAC inhibitorstargeted cancer gene therapy

Identifiers

PMID29690504
PMCPMC5923380
OpenAlexW2799816054

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.